London, UK-based MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, has closed a $6.2 million (£5 million) seed funding extension round.
The investment in MultiOmic Health was led by Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve Ventures.
MultiOmic has raised $8.6 million to date.